Seeking Alpha

Dyadic International, Inc. and Proliant Health and Biologicals announce Recombinant Albumin Development and Commercialization Partnership

JUPITER, Fla., June 28, 2024 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (DYAI), announced today that they have entered into a development and commercialization partnership with Proliant Health and ...
Business Insider

Dyadic Applied BioSolutions and Proliant Health & Biologicals Announce Commercial Launch of Recombinant Human Albumin

JUPITER, Fla. and ANKENY, Iowa, Feb. 17, 2026 (GLOBE NEWSWIRE) -- Dyadic Applied BioSolutions (“Dyadic”, “we”, “us”, “our”, or the “Company ...
Nasdaq

Dyadic’s C1 Platform to be Used to Produce Vaccines for Humans and Animals in Africa

JUPITER, Fla., Nov. 20, 2023 (GLOBE NEWSWIRE) -- Dyadic International, Inc. ("Dyadic", "we", "us", "our", or the "Company") (NASDAQ: DYAI), a global biotechnology ...
Seeking Alpha

Dyadic International, Inc. (DYAI) Q4 2024 Earnings Call Transcript

Good evening and welcome to Dyadic International's Year-End 2024 Conference Call. Currently, all participants are in a listen-only mode. Following management's prepared remarks, there will be a brief ...
Nasdaq

Dyadic and Phibro Animal Health Announce Exclusive License Agreement to Develop and Commercialize Animal Health Vaccine

The exclusive license agreement between Dyadic and Phibro utilizes Dyadic engineered C1-cells to produce specific targeted antigens for development and commercialization of a poultry vaccine for a ...
Finanznachrichten

Dyadic International, Inc.: Dyadic Applied BioSolutions and Proliant Health & Biologicals Announce Commercial Launch of Recombinant Human Albumin

Under the terms of the agreement, Dyadic will receive a share of profits from Proliant's commercial sales of recombinant human albumin products. "This launch is a clear validation of Dyadic's ...